A Phase 1 interventional study of "Metformin" and "Rosuvastatin" seperately and JLP-1310 in Diabetes and Hyperlipidemias, sponsored by Jeil Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-29.
Sponsored by Jeil Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
A randomized, open-label, single dose, crossover study to compare the pharmacokinetic characteristics of the co-administration of metformin SR and rosuvastatin and JLP-1310 in healthy male volunteers.
821 studies on the registry are indexed under Hyperlipidemias; 105 are open to participants now.
This study's enrollment of 42 is below the median of 87 across 691 interventional studies indexed under Hyperlipidemias.
Browse Hyperlipidemias studies →Jeil Pharmaceutical Co., Ltd. is the lead sponsor of 35 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Period I: administration of "Metformin" and "Rosuvastatin" seperately Period II: JLP-1310
Drug: "Metformin" and "Rosuvastatin" seperately · Drug: JLP-1310
Period I: JLP-1301 Period II: administration of "Metformin' and "Rosuvastatin" seperately
Drug: "Metformin" and "Rosuvastatin" seperately · Drug: JLP-1310
administration of "Metformin" and "Rosuvastatin" seperately
administration of JLP-1310
AUCt of Metformin and rosuvastatin
Time frame: 48 hours
Cmax of Metformin and rosuvastatin
Time frame: 48 hours
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jeil Pharmaceutical Co., Ltd.